NGM Biopharmaceuticals, Inc. Common Stock
NGM
NGM was delisted on the 4th of April, 2024.
84 hedge funds and large institutions have $667M invested in NGM Biopharmaceuticals, Inc. Common Stock in 2020 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 32 increasing their positions, 18 reducing their positions, and 10 closing their positions.
110% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 10
78% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 18
66% more capital invested
Capital invested by funds: $402M → $667M (+$264M)
15% more funds holding
Funds holding: 73 → 84 (+11)
1.56% more ownership
Funds ownership: 48% → 49.56% (+1.6%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$17.9M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$10.1M |
| 3 |
PS
Peter Svennilson
|
+$7.34M |
| 4 |
Morgan Stanley
New York
|
+$3.49M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$1.55M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$11.5M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$3.38M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$2.82M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
-$2.4M |
| 5 |
Millennium Management
New York
|
-$1.59M |
NGM Hedge Fund Activity: Q2 2020 in Review
84 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in NGM Biopharmaceuticals, Inc. Common Stock (NGM) for Q2 2020, worth a combined $667M — up 66% from $402M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new NGM positions and 10 closed out — a net gain of 11 holders — while 32 added to existing stakes and 18 trimmed.
The largest buyer was Vanguard Group, adding an estimated $17.9M. The largest seller was Royal Bank of Canada, exiting entirely with an estimated $11.5M sold.
- 84 institutional investors held NGM Biopharmaceuticals, Inc. Common Stock (NGM) as of Q2 2020, up from 73 in Q1 2020.
- Funds reported $667M of NGM Biopharmaceuticals, Inc. Common Stock stock for Q2 2020, up 66% quarter-over-quarter.
- 21 funds opened new NGM Biopharmaceuticals, Inc. Common Stock positions in Q2 2020 and 10 closed out, a net change of +11 holders.
- The largest NGM Biopharmaceuticals, Inc. Common Stock buyer in Q2 2020 was Vanguard Group, an estimated $17.9M added.
- The largest NGM Biopharmaceuticals, Inc. Common Stock seller in Q2 2020 was Royal Bank of Canada, an estimated $11.5M sold.
Based on aggregated 13F filings for Q2 2020.